Results 161 to 170 of about 1,266 (177)
Some of the next articles are maybe not open access.
Olodaterol for the treatment of chronic obstructive pulmonary disease: a narrative review
Expert Opinion on Pharmacotherapy, 2018Inhaled bronchodilators are the key-stone of chronic obstructive pulmonary disease (COPD) management. Olodaterol 5 µg, a long-acting β2-adrenoceptor agonist (LABA) is one such bronchodilator indicated as a once-daily maintenance therapy. Areas covered: This article reviews the several trials that have assessed olodaterol as a COPD therapy.
openaire +2 more sources
Olodaterol: A Review of Its Use in Chronic Obstructive Pulmonary Disease
Drugs, 2015Olodaterol (Striverdi(®) Respimat(®)) is an inhaled long-acting β2-adrenoceptor agonist (LABA) indicated as a once-daily maintenance bronchodilator therapy in adults with COPD. Several well-designed phase III trials have assessed use of the drug over 6 or 48 weeks in this patient population.
openaire +2 more sources
Tiotropium Bromide/Olodaterol as Maintenance Treatment for Patients with COPD
Clinical Medicine Reviews in Vascular Health, 2016Chronic obstructive pulmonary disease (COPD) requires appropriate treatment regimens, since it is a major cause of morbidity and mortality worldwide. Recently, several clinical trials confirmed that compared with tiotropium monotherapy and combination therapy of long-acting β2 agonist (LABA) plus inhaled corticosteroids (ICSs), maintenance therapy with
openaire +1 more source
New Drugs: Dulaglutide, olodaterol hydrochloride, and vorapaxar sulfate
Journal of the American Pharmacists Association, 2015Daniel A, Hussar, Dean R, Wetty
openaire +2 more sources